www.modernatx.com Open in urlscan Pro
108.138.17.95  Public Scan

Submitted URL: https://i.modernatx.com/OTQ5LUJERy0yNzQAAAGMyxLTqCz-tG70TNk7zAVg280QHAEbZ6y5SuDRm8x8GxcX7UjNjg1nTzNpqOkK6n6_8XrOhlg=
Effective URL: https://www.modernatx.com/?tc=em_5rtj0d2&cc=4013&mkt_tok=OTQ5LUJERy0yNzQAAAGMyxLTqIIZKi8BdlF1Ao_EAYM3k3Qe6c3KlNX9cxKiAE3g-...
Submission: On July 06 via api from US — Scanned from DE

Form analysis 0 forms found in the DOM

Text Content

Skip to main content
 * mRNA pipeline
 * Careers
 * Newsroom
 * Blogs
 * |
 * Health Care Professionals
 * Investors
 * Clinical trials

 * About Us
   
 * The Power of mRNA
   
 * Research
   
 * Responsibility
   
 * COVID-19
   

USA



English

Search


LANGUAGE OPTIONS

United States

English




LOOKING FOR ANOTHER LOCATION?


ASIA PACIFIC



Australia

English


Japan

日本


Hong Kong

中文


South Korea

한국어


Taiwan

中文



EUROPE



France

Français


Germany

Deutsch


Italy

Italiano


Netherlands

Nederlands


Spain

Español


Switzerland

Deutsch

Français

Italiano


United Kingdom

English



NORTH AMERICA



Canada

English

Français


United States

English



SOUTH AMERICA



LATAM

Español


LATAM

Português



IMPACTING HUMAN HEALTH: REFLECTING ON OUR ESG PROGRESS

Read Shannon Thyme Klinger's blog post

1/2





NewsJob opportunitiesBlogs

Moderna Announces Global Regulatory Submissions For Its Respiratory Syncytial
Virus (RSV) Vaccine, MRNA-1345

05 July 2023

Moderna Submits Regulatory Application to the European Medicines Agency for Its
Updated COVID-19 Vaccine

03 July 2023

Taking Action and Raising Awareness: The Impact of Cytomegalovirus (CMV)

28 June 2023

Moderna Files for FDA Authorization of Its Updated COVID-19 Vaccine

22 June 2023

Impacting Human Health: Reflecting on our ESG Progress

14 June 2023

Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA(R)
(pembrolizumab) Demonstrated a Statistically Significant and Clinically
Meaningful Improvement in Distant Metastasis-Free Survival in Patients with
High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA

05 June 2023
View all news

12
Years of progress
48
Products in pipeline
35
Ongoing clinical trials


MEET MODERNA

Moderna’s goal is to deliver on the promise of mRNA science to create a new
generation of transformative medicines for patients.

See our mission




JOIN US AND CHANGE THE WORLD OF MEDICINE

Life at Moderna




SO, WHAT IS MRNA?

Messenger RNA (mRNA) already exists in your body. It carries a “message” -
instructions that direct your cells what to do.

Fighting disease differentlyLimitless treatmentsHelping more peopleMore
medicines, faster


FIGHTING DISEASE DIFFERENTLY

mRNA medicines fight diseases in a different way than traditional medicine by
prompting your immune system to create the tools to treat or prevent disease.

Learn more about mRNA



LIMITLESS TREATMENTS

We believe that if mRNA can treat one disease, it can treat many diseases. We
will use mRNA to treat diseases for which there are currently no treatments.

Learn more about mRNA



HELPING MORE PEOPLE

mRNA medicine contains no animal products or preservatives, making medicine
accessible for as many people as possible.

Learn more about mRNA



MORE MEDICINES, FASTER

Our platform enables rapid design, research and testing of multiple mRNAs,
within days. Our novel production methods allow us to get medicines to more
people, faster.

Learn more about mRNA

1/4


MEET HAMILTON


SENIOR DIRECTOR, VACCINE ACCESS AND PARTNERSHIPS

It normally takes 10-15 years to develop a vaccine. With the COVID-19 pandemic,
Hamilton knew she didn’t have years – she led her team from development and into
early trials within two months.

Meet more team members




POPULAR MEDIA

More media

See Moderna’s Ad from the 2022 US Open

Video

25 August 2022

Questions & Answers with Rose Loughlin

Blog

11 February 2022

The Future of Vaccines with Moderna CEO Stéphane Bancel

Podcast

25 October 2021

Moderna and Flagship Pioneering: Noubar Afeyan

Podcast

11 October 2021


2022 ESG REPORT

Our journey to building the best version of Moderna

Click here to read our 2022 report


INVESTORS

 * Investors overview


NEWSROOM

 * News and media
 * Media kit


PATENTS

 * Patents


MEDIA CENTER

 * All media
 * Blogs
 * Videos
 * Podcasts


PARTNERSHIPS

 * Strategic collaborators


CAREERS

 * Life at Moderna
 * People behind the science
 * Awards
 * Join our team


INNOVATION INCUBATOR

 * New Venture Labs



 * Terms of use
 * Privacy statement
 * Contact Moderna
 * Sitemap

© 2023 Moderna, Inc.



We collect cookies

This website stores data such as cookies to enable essential site functionality,
as well as marketing, personalization, and performance. Privacy Statement

 * Strictly Necessary
   
   These items are required to enable basic website functionality.
   
   

 * Marketing
   
   These items are used to deliver advertising that is more relevant to you and
   your interests. They may also be used to limit the number of times you see an
   advertisement and measure the effectiveness of advertising campaigns.
   Advertising networks usually place them with the website operator’s
   permission.
   
   

 * Personalization
   
   These items allow the website to remember choices you make (such as your user
   name, language, or the region you are in) and provide enhanced, more personal
   features. For example, a website may provide you with local weather reports
   or traffic news by storing data about your current location.
   
   

 * Performance
   
   These items help the website operator understand how its website performs,
   how visitors interact with the site, and whether there may be technical
   issues. This storage type usually doesn’t collect information that identifies
   a visitor.
   
   

Show Details Show Less
Deny Accept All